aTyr Pharma 将来の成長

Future 基準チェック /56

aTyr Pharmaは、62.5%と80.2%でそれぞれ年率62.5%で利益と収益が成長すると予測される一方、EPSはgrowで63%年率。

主要情報

62.5%

収益成長率

63.0%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	80.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	18 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:471A - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	43	-60	-65	-145	7
12/31/2025	4	-68	-57	-58	7
12/31/2024	0	-67	-58	-76	6
9/30/2024	0	-64	-67	-67	N/A
6/30/2024	1	-58	-64	-63	N/A
3/31/2024	1	-54	-58	-55	N/A
12/31/2023	0	-50	-37	-33	N/A
9/30/2023	11	-43	-38	-33	N/A
6/30/2023	10	-45	-40	-35	N/A
3/31/2023	10	-45	-35	-32	N/A
12/31/2022	10	-45	-44	-42	N/A
9/30/2022	N/A	-46	-40	-40	N/A
6/30/2022	N/A	-41	-39	-39	N/A
3/31/2022	N/A	-39	-38	-37	N/A
12/31/2021	N/A	-34	-33	-33	N/A
9/30/2021	2	-30	-31	-30	N/A
6/30/2021	2	-29	-25	-24	N/A
3/31/2021	2	-25	-23	-23	N/A
12/31/2020	10	-16	-16	-15	N/A
9/30/2020	9	-17	-15	-15	N/A
6/30/2020	9	-16	-14	-14	N/A
3/31/2020	8	-16	-12	-12	N/A
12/31/2019	0	-24	-20	-20	N/A
9/30/2019	0	-24	-20	-20	N/A
6/30/2019	0	-25	-22	-22	N/A
3/31/2019	N/A	-30	-27	-27	N/A
12/31/2018	N/A	-35	-32	-31	N/A
9/30/2018	N/A	-40	-37	-37	N/A
6/30/2018	N/A	-44	N/A	-39	N/A
3/31/2018	N/A	-45	N/A	-39	N/A
12/31/2017	N/A	-48	N/A	-42	N/A
9/30/2017	N/A	-49	N/A	-44	N/A
6/30/2017	N/A	-52	N/A	-50	N/A
3/31/2017	N/A	-55	N/A	-54	N/A
12/31/2016	N/A	-58	N/A	-53	N/A
9/30/2016	N/A	-62	N/A	-51	N/A
6/30/2016	N/A	-59	N/A	-46	N/A
3/31/2016	N/A	-55	N/A	-43	N/A
12/31/2015	N/A	-48	N/A	-37	N/A
9/30/2015	N/A	-38	N/A	-33	N/A
6/30/2015	N/A	-33	N/A	-29	N/A
3/31/2015	N/A	-28	N/A	-23	N/A
12/31/2014	N/A	-25	N/A	-23	N/A
9/30/2014	N/A	-24	N/A	-21	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 471Aは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: 471A今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 471A今後 3 年以内に収益を上げることが予想されます。

収益対市場: 471Aの収益 ( 80.2% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 471Aの収益 ( 80.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 471Aの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

aTyr Pharma 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

Recent updates

New minor risk - Profitability

Independent Director recently bought €170k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

Independent Chairman of the Board recently bought €81k worth of stock

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

New major risk - Share price stability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Independent Director recently bought €410k worth of stock

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Independent Director recently bought €163k worth of stock

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific Advisor

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

New 90-day high: €6.35

aTyr Pharma, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

aTyr Pharma, Inc. to Report Q3, 2020 Results on Nov 12, 2020

aTyr Pharma, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

aTyr Pharma, Inc. announced that it expects to receive $20 million in funding from Aspire Capital Partners, LLC

aTyr Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘